Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma

Sponsor

Cancer Research UK (Other)

Overall Status

Completed

CT.gov ID

NCT01390571

Collaborator

(none)

Enrollment

Locations

71.7

Duration (Months)

4.9

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

RATIONALE: Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Olaparib may help temozolomide kill more tumor cells by making tumor cells more sensitive to the drug.

PURPOSE: This phase I trial is studying the side effects and best dose of olaparib and temozolomide in treating patients with relapsed glioblastoma.

Condition or Disease	Intervention/Treatment	Phase
Brain and Central Nervous System Tumors	Drug: olaparib Drug: temozolomide Genetic: gene expression analysis Genetic: protein expression analysis Other: laboratory biomarker analysis Other: pharmacological study Procedure: diffusion-weighted magnetic resonance imaging Procedure: dynamic contrast-enhanced magnetic resonance imaging Procedure: therapeutic conventional surgery	Phase 1

Detailed Description

OBJECTIVES:

Primary

To determine whether olaparib crosses the blood-brain barrier (BBB) and achieves tumor penetration in patients with relapsed glioblastoma. (Stage 1)
To determine the safety and tolerability of the combination of olaparib and temozolomide in patients with relapsed glioblastoma. (Stage 2)

Secondary

To assess BBB disruption and BBB permeability in patients with relapsed glioblastoma. (Stage 1 and stage 2 maximum-tolerated dose [MTD] expansion cohort)
To assess the possible anti-tumor activity of the combination of olaparib and temozolomide in patients with relapsed glioblastoma. (Stage 2)

Tertiary

To assess biological markers as possible predictors of olaparib efficacy in patients with glioblastoma.
To optimize techniques for measuring DNA damage responses to PARP inhibition in tumor tissue.
To determine plasma concentration of olaparib at the time of surgery in patients with glioblastoma.
To evaluate the PARP inhibition at the time of surgery in peripheral blood mononuclear cells (PBMCs).

OUTLINE: This is a multicenter, dose-escalation study.

Stage 1: Patients receive fixed-dose oral olaparib twice daily for 3 days prior to resection and then receive a dose of oral olaparib on the morning of the resection. After the surgical resection, patient receive standard of care treatment. Patients undergo dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) scans to assess the disruption and permeability of the blood-brain barrier (BBB).

Stage 1 is complete and it was proven that olaparib can cross the BBB and achieve tumour penetration in glioblastoma patients.

Stage 2: Patients receive escalating doses of oral olaparib once or twice daily for 3 days prior to resection and then receive a dose of oral olaparib on the morning of the resection. After recovery from surgery, patients receive oral olaparib once or twice daily and oral temozolomide once daily on days 1-42. Treatment repeats every 8 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients may receive 3 additional courses of treatment in the absence of disease progression.

Once the maximum tolerated dose (MTD) is established, 10 more patients are treated at the MTD as stage 2 MTD expansion cohort. These patients also undergo DCE-MRI and DWI scans.

All patients undergo blood collection periodically for pharmacokinetic and pharmacodynamic studies.

After completion of study treatment, patients are followed up for 28 days and then monthly until resolution of study drug-related adverse events.

Peer Reviewed and Funded or Endorsed by Cancer Research UK.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

34 participants

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma

Study Start Date :

Jul 1, 2011

Actual Primary Completion Date :

Jun 20, 2017

Actual Study Completion Date :

Jun 20, 2017

Outcome Measures

Primary Outcome Measures

Detection of olaparib in tumor tissue using liquid chromatography mass spectrometry (LC-MS) seen in at least 1 out of the 6 patients treated in stage 1 of the study []
Maximum-tolerated dose of olaparib in combination with temozolomide (stage 2) []
Toxicity profile and dose-limiting toxicity as assessed by NCI CTCAE Version 4.02 (stage 2) []

Secondary Outcome Measures

Measurement of blood-brain barrier (BBB) disruption and permeability biomarkers by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) (stage 1 and stage 2 MTD expansion cohort) []
Progression-free survival at 6 months post-surgery as assessed by the Response Assessment in Neuro-Oncology Working Group (RANO) criteria from conventional MRI and clinical assessment (stage 2) []

Other Outcome Measures

Gene copy number analysis of DNA repair genes []
Quantification of DNA repair gene expression []
Measurement of methylation of the MGMT promoter gene by bisulfite modification of DNA and pyrosequencing []
Measurement of microsatellite instability by Multiplex PCR []
Measurement of mismatch repair (MMR) gene expression by quantitative real time polymerase chain reaction (QRT-PCR) analysis []
Measurement of phosphatase and tensin homolog (PTEN) protein and gene expression []
Quantification of global DNA strand breaks in tumour tissue by Immunostaining for γH2AX []
Measurement of Rad51 foci and nuclear staining intensity as markers of homologous recombination (HR) repair activity []
Plasma levels of olaparib measured by LC-MS []
PARP inhibition measured by validated assays []
Detection of olaparib in tumour margin tissue using LC-MS []

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

DISEASE CHARACTERISTICS:

Histologically confirmed grade IV glioblastoma
Radiological diagnosis of recurrent or progressive disease according to Response Assessment in Neuro-Oncology Working Group (RANO) criteria, which is suitable for palliative resection
Must have an adequate amount of tumor tissue available
Previously received first-line treatment with radical radiotherapy, or chemoradiation followed by adjuvant chemotherapy
No prior chemotherapy for recurrent disease

PATIENT CHARACTERISTICS:

WHO performance status 0-2
Life expectancy > 12 weeks
Hemoglobin ≥ 10.0 g/dL
Absolute neutrophil count ≥ 1.5 x 10^9/L
Platelet count ≥ 100 x 10^9/L
Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)
ALT or AST ≤ 2.5 times ULN
Calculated creatinine clearance ≥ 50 mL/min OR isotope clearance measurement ≥ 50 mL/min (uncorrected)
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use one (male) or two (female) highly effective forms of contraception 4 weeks prior to, during, and for 6 months after completion of study therapy
Able to swallow and retain oral medications
Not at high medical risk due to non-malignant systemic disease, including active uncontrolled infection
No known hepatitis B, hepatitis C, or HIV seropositivity
No concurrent congestive heart failure, prior history of NYHA class III-IV cardiac disease, prior history of cardiac ischemia, or prior history of cardiac arrhythmia within the past 12 months
No grand mal seizures occurring ≥ 3 times per week over the past month
No gastrointestinal disorders likely to interfere with absorption of the study medication
No known hypersensitivity to any of the components of olaparib
No known hypersensitivity to temozolomide (TMZ) or any of its components, or to dacarbazine (DTIC) (for patients enrolled in stage 2 study only)
No known lactose intolerance (for patients enrolled in the stage 2 study only)
No metal fragments in the eyes (shrapnel or bullet injuries are excluded on the basis of their unsuitability to undergo MRI scans)
No other condition which, in the Investigator's opinion, would not make the patient a good candidate for the clinical trial

EXCLUSION CRITERIA:

See Disease Characteristics
No ongoing toxic manifestations from previous treatments except for alopecia or grade 1 toxicities which, in the opinion of the Investigator and the Drug Development Office (DDO), should not exclude the patient
At least 12 weeks since prior radiotherapy, endocrine therapy, or immunotherapy
At least 6 weeks since prior major surgery
At least 4 weeks since prior chemotherapy
At least 4 weeks since prior immunizations with live vaccines (or expected to receive vaccines during the trial and up to at least 6 months after receiving last study treatment), including BCG and yellow fever vaccines
No prior PARP inhibitors, including olaparib
No prior major thoracic or abdominal surgery from which the patient has not yet recovered
No prior heart surgery
No pacemakers
No change to systemic steroids dose within 5 days prior to enrollment (i.e., must be on a stable dose at time of enrollment and remain on a stable dose throughout the treatment period)
No herbal supplements and/or ingestion of foods known to modulate CYP3A4 enzyme activity from time entered on screening period until 28 days after the last dose of study medication
No concurrent drugs known to be potent inducers of CYP3A4, including phenytoin, carbamazepine, phenobarbital, rifampicin, rifapentine, rifabutin, nevirapine, modafinil, or St. John wort (wash-out period for phenobarbital is 5 weeks, 3 weeks for all others)
No concurrent drugs known to be potent inhibitors of CYP3A4, including ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin, or nelfinavir (wash-out period is 1 week)
No concurrent or planned participation in another interventional clinical study
Participation in an observational study is acceptable
No concurrent warfarin (patients requiring anticoagulation should be given subcutaneous low molecular weight heparin)
No other concurrent anticancer therapy (including radiotherapy) or investigational drugs
No blood transfusions within 4 weeks prior to study start of features suggestive of myelodysplasia or AML

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Bristol Haematology and Oncology Centre	Bristol	England	United Kingdom	BS2 8ED
2	Addenbrooke's Hospital	Cambridge	England	United Kingdom	CB2 0QQ
3	Christie Hospital	Manchester	England	United Kingdom
4	Royal Marsden Hospital	Sutton	England	United Kingdom
5	Beatson West of Scotland Cancer Centre	Glasgow	Scotland	United Kingdom
6	Queen Elizabeth Hospital	Birmingham		United Kingdom	B15 2TH
7	Western General Hospital	Edinburgh		United Kingdom	EH4 2XU